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To determine the genetic basis of familial frontotemporal lobar degeneration (FTLD) with
amyotrophic lateral sclerosis (ALS) we performed a clinical and genetic analysis of an
affected family. A 51-year-old man with behavioral variant FTLD with ALS had a family history
of the disease suggestive of autosomal dominant inheritance with incomplete penetrance.
Genetic studies in this patient demonstrated the presence of an amplified hexanucleotide
repeat (>30) polymorphism in the chromosome 9 open reading frame 72 (C9ORF72) gene
which was previously identified as a cause of FTLD. Five others unaffected from the fam-
ily were negative (all had less than 11 repeats). Because of the clinical and pathological
overlap between FTLD and AD we performed a larger genome-wide association study and
did not find association of single nucleotide polymorphisms (SNPs) in the C9ORF72 gene
with Alzheimer’s disease (AD) risk. Bioinformatic analysis of C9ORF72 using the Gene
Expression Omnibus database showed expression differences in patients with muscular
dystrophy, neural tube defects, and schizophrenia. We also report analysis of gene expres-
sion in brain regions using the Allen Human Brain Atlas. Defects in this recently reported
gene are now believed to be the most common cause of inherited ALS and an important
cause of inherited FTLD. Our work suggests that the gene may also be important in other
neurological and psychiatric conditions.
Keywords: dementia, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, motor neuron disease,
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INTRODUCTION AND BACKGROUND
Frontotemporal lobar degeneration (FTLD), originally described
by Alois Alzheimer’s contemporary Arnold Pick, has been recog-
nized as the second leading cause of dementia in people under
the age of 65 (Ratnavalli et al., 2002). Its behavioral variant causes
abnormal social behavior characterized as disinhibition with emo-
tional lability and inappropriate laughter. FTLD may be found
alone or accompanied by corticobasal degeneration, parkinson-
ism, or amyotrophic lateral sclerosis (ALS). As many as 50% of
ALS patients have cognitive and behavioral deficits and about
half of FTLD cases have motor neuron impairment. One quar-
ter to one half of FTLD cases have an autosomal dominant pattern
of inheritance and several genes on chromosome 9p have been
linked to familial FTLD with ubiquitin immunoreactive inclusions
(Vance et al., 2006; Liscic et al., 2008). A genetic locus associated
with FTLD with ALS has recently been identified as a hexanu-
cleotide repeat located on chromosome 9, open reading frame
72 (C90RF72; Mok et al., 2012; DeJesus-Hernandez et al., 2011;
Laaksovirta et al., 2010). This gene is believed to be the most
common cause of familial FTD-ALS. We describe an additional
case and report results of a genetic association analysis in a very
large Alzheimer disease (AD) dataset and a bioinformatic analysis
demonstrating altered expression of C9ORF72 in patients with
other neurological conditions and expression patterns in the brain.
The studies described below were approved by the Institu-
tional Review Board of the University of Louisville Health Sciences
Center and informed consent was obtained from all subjects.
CASE REPORT
A 51-year old Caucasian man presented to the hospital with falls
beginning in October, 2010. Weakness and retraction of fingers
in both hands with gradual cognitive decline were noticed at that
time and he could no longer take care of himself, needing help
with bathing, with wandering, denial of illness, and inappropriate
emotional expression. When he was asked why he was in the Emer-
gency Room, he said that his computer did not work. Past history,
social history, and review of systems were not contributory. Mental
status exam demonstrated moderate dementia with word finding
difficulties, trouble naming object parts, inappropriate laughter,
motor impersistence, inability to follow commands, impaired cal-
culations, inappropriate smiling, and laughing throughout the
exam. There was diffuse weakness and wrist drop bilaterally with
muscle atrophy in the hands and legs, difficulty walking, and fas-
ciculations in all four extremities. Sensory exam and deep tendon
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reflexes were normal. Laboratory tests for routine studies and
non-genetic causes of ALS or dementia were negative. Positron
emission tomography with 18-fluorodeoxyglucose was compati-
ble with advanced frontotemporal dementia with bilateral anterior
frontal and anterior temporal hypometabolism, including the cin-
gulate gyrus. Glucose metabolism was relatively preserved in the
basal ganglia. MRI imaging of the brain showed diffuse cortical
atrophy.
FAMILY HISTORY
The patient’s mother is alive and well at age 74. His father died of a
brain tumor at age 42. His father’s sister had early onset dementia
at age of 50 with ALS and died at age 62 (IIH; Figure 1). Her son
also had early onset dementia with ALS and died at the age of 59
(IIID). The patient’s paternal grandfather also had dementia and
died in his 60’s (IE).
An autopsy performed in 1991 of the patient’s father’s sister
(IIH) demonstrated severe cerebral cortical atrophy, most promi-
nent in the frontal poles, and to a lesser extent in the parietal and
temporal lobes. The cerebellum was also atrophic. The lateral ven-
tricles were symmetrically enlarged as was the third ventricle. The
ventral roots were small and demyelination of the lateral columns
was seen in the cervical enlargement. Degenerative changes in
nerve cells were observed in the cortex without gliosis. Senile
plaques or neurofibrillary tangles were not detected. Loss and
degenerative changes of the anterior horn cells was observed with
thinning of the anterior roots.
The patient’s first cousin (IIID; Figure 1) died in 2009 at
age 59 with dementia, fasciculations, weakness, spasticity, hyper-
eflexia, and cortical atrophy after an illness of 1 year duration.
Autopsy demonstrated atrophy of the spinal cord with neuronal
loss and gliosis in the anterior horns, cortex, hippocampus (CA1
and subiculum), hypoglossal nucleus, and basal ganglia. Ubiquitin
positive inclusions were found in cell bodies and neurites in the
right and left hippocampi including the granular cells of the den-
tate gyrus, the tegmentum of the medulla, and the gray matter of
the spinal cord. Neurofibrillary tangles were found in the neurons
in the right and left hippocampi. Amyloid Beta protein deposition
was not detected.
Incomplete penetrance is suggested by the absence of the dis-
ease in four out of the five children of affected subject IE (the
proband’s paternal grandfather) and also the absence of disease in
three out of the four children of affected subject IIH (the proband’s
father’s sister). The pedigree was altered to preserve confidentiality.
RESULTS: GENETIC TESTING
The proband was positive for a non-coding GGGGCC hexanu-
cleotide repeat in the gene C9ORF72 (>30 repeats). Five other
unaffected from the family were negative. All had less than 11
repeats.
ASSOCIATION OF C9ORF72 WITH ALZHEIMER DISEASE
We tested the association of 45 genotyped and imputed single
nucleotide polymorphisms (SNPs) in C9ORF72 with risk of AD
in a large genome-wide association study (GWAS) dataset con-
taining 8,309 late onset AD cases and 7,366 controls (Naj et al.,
2011). Nominally significant results were observed with four SNPs
(p< 0.05), but none of these findings remained significant after
correction for multiple testing. Association with C9ORF72 was
also not significant (p= 0.12) using the VEGAS gene-based test
method (Liu et al., 2010). These findings suggest that variants in
C9ORF72 do not influence AD risk.
BIOINFORMATIC ANALYSIS OF C9ORF72
Because the function of C9ORF72 is unknown, we queried the
Gene Expression Omnibus (GEO) database at the National Center
for Biotechnology Information (NCBI), one of the largest public
repositories for gene expression data1, for evidence of differen-
tial expression of this gene in brain or the CNS. This database
stores individual gene expression profiles from curated “DataSets”
and can be used to search for profiles of interest based on gene
annotation or pre-computed profile characteristics.
Three independent searches were performed on the GEO pro-
files database. These searches were based on the“Flag Type”field in
the GEO profiles database which categorizes profiles that exhibit
specific types of subset effects. GEO DataSets are partitioned into
subsets that reflect experimental design. Profiles are flagged as
having subset effects if they display differential expression across
experimental variables. The subset effect scoring method is ad hoc,
taking into account group medians, means, deviations inside the
groups, penalties, and arbitrary cutoff thresholds. This flag is sim-
ply an attempt to give potentially differentially regulated genes
higher visibility, and is not intended to provide an absolute deter-
mination of significance. Three search terms were used with the
following relevant results:
Search: (C9orf72) and “rank subset effect” (flag type)
The highlight of this search term was an analysis of skeletal muscles
from patients with limb girdle muscular dystrophy 2A (LGMD2A).
LGMD2A is a recessive genetic disorder caused by mutations in
calpain 3 (CAPN3). This study showed that C9ORF72 was down-
regulated in muscle samples from 10 patients with calpainopathy
compared to muscle samples from 10 healthy controls.
Search: (C9orf72) and “value subset effect” (flag type)
Six studies unrelated to brain or the CNS were flagged by this
search term.
Search: C9orf72 (gene symbol) and “sample outlier” (flag type)
Studies showing differential expression of C9ORF72 of several
brain-related disorders or processes were identified by this search
term. Expression was decreased in amniotic fluid samples from
pregnant women carrying fetuses with neural tube defects (NTDs)
diagnosed during ultrasound examination and increased in imma-
ture dendritic cells subjected to hypoxia in vitro. Another study
demonstrated thatC9ORF72 is overexpressed in cerebellar cortical
samples from schizophrenia patients.
We also examinedC9ORF72 expression using the Allen Human
Brain Atlas for the Developing Human Brain datasets and found
areas of its expression in the occipital and temporal lobes, and
cerebellar cortex (Allen Brain Atlas Resources, Seattle, WA, USA:
1http://www.ncbi.nlm.nih.gov/geoprofiles
Frontiers in Neurology | Neurogenomics October 2012 | Volume 3 | Article 136 | 2
Friedland et al. ALS-FTD with a chromosome 9p21 hexanucleotide repeat
FIGURE 1 | Pedigree.The proband is subject IIIA.
Allen Institute for Brain Sciences, 20092). The gene was propor-
tionally more highly expressed in the cerebellum, cingulate sulcus,
and hypothalamus, compared to the caudate, and temporal pole.
Analysis of curated information in the BrainSpan Atlas of the
Developing Human Brain3 also showed that C9ORF72 expression
at age 12 weeks pre-natally is greatest in the dorsolateral pre-
frontal cortex, ventrolateral prefrontal cortex, medial prefrontal
cortex, and inferolateral temporal cortex. At age 6 months and
between ages 1 and 3 years, expression decreases proportionally
compared to the other stages in the aforementioned regions and
in the orbital frontal cortex, mediodorsal nucleus of the thalamus,
primary visual cortex, and hippocampus.
DISCUSSION
The highest prevalence of ALS is found in Finland and in a study
of Finnish cases, over 40% of familial ALS was attributed to
a locus on chromosome 9p21 (Laaksovirta et al., 2010). Cases
2http://www.brainmap.org
3http://alleninstitute.org/science/public_resources/brainspan.html
of ALS, FTD, and FTD-ALS, with type II TAR DNA-binding
protein-43 (TDP-43) pathology, have also been associated with
chromosome 9. Three recent reports have identified a locus on
chromosome 9p21 for familial autosomal dominant FTD-ALS
(Mok et al., 2012; DeJesus-Hernandez et al., 2011; Laaksovirta
et al., 2010). The repeat expansion of a non-coding GGGGCC
hexanucleotide repeat in C9ORF72 was associated with the dis-
ease in the large FTD-ALS kindred and TDP-43 based pathol-
ogy. It has been proposed that the repeat expansion leads to
the loss of one alternately spliced C9ORF72 transcript and for-
mation of nuclear RNA foci. The mutation is in a non-coding
region of the gene with no known function. There may be 2–
20 repeats of GGGGCC in the normal gene and several hun-
dred more in the mutant versions. The expanded repeat is tran-
scribed into RNA, causing the resultant protein to be misfolded,
with toxic aggregates, disrupting cellular function. While the
C9ORF72 gene is believed to be non-coding the RNA which
it produces may interfere with expression of another gene or
genes. Toxic attributes of the abnormal RNA has also been pro-
posed (Renton et al., 2011). It has been suggested that there
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is a single founder for this form of the disease (Mok et al.,
2012).
This repeat expansion was also found in one third of famil-
ial ALS cases of outbred European decent, and it was more than
twice as common as mutations in the SOD gene as a cause of
familial ALS, and more than three times as common as TDP-43,
fused in sarcoma (FUS), or optineurin (OPTN) mutations com-
bined. It has been proposed that the mutation accounts for∼40%
of cases of familial ALS in persons of European descent. SOD1
mutations are thought to be responsible for∼15% of familial ALS
cases. Sporadic ALS may also be caused by the mutation. It was also
noted that age of symptom onset varied widely in patients carrying
the pathogenic hexanucleotide expansion, some not developing
weakness until their ninth decade. The age of onset in our fam-
ily is similar to that reported by others, and anticipation was not
observed. The behavioral variant FTLD was also seen in the series
of DeJesus-Hernandez et al. (2011), in most cases. In the Finnish
cohort reported by Renton et al. (2011), several patients presented
with non-fluent progressive aphasia.
We found no evidence for association of polymorphisms in
C9ORF72 with AD in a large GWAS dataset, as has been reported
by Rollinson et al. (2012). Bioinformatic analysis of this gene using
the GEO database showed changes in gene expression of C9ORF
72 in patients with muscular dystrophy, NTDs, and schizophrenia.
We also report analysis of gene expression in brain regions using
the Allen Human Brain Atlas. Mutations in this recently reported
gene are now believed to be the most common cause of inherited
ALS and an important cause of inherited FTLD. Our work sug-
gests that the gene may also be important in other neurological
conditions.
These data, together with the recent previous reports, are con-
sistent with the view that this repeat expansion underpins a large
proportion of those families in which ALS and FTD co-occur. The
mechanisms by which the repeat expansion causes dysfunction
remains to be established.
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